Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Endo USA Inc., a Keenova Therapeutics Company | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare key clinical outcomes of collagenase clostridium histolyticum injections versus surgery for the management of Peyronie's Disease.
After eligible patients have been informed about the study protocol and risks and consent have been given, men will be randomly assigned into either the collagenase clostridium histolyticum + penile traction therapy (CCH + PTT) group or to the surgery + penile traction therapy (surgery + PTT) group. Those in the CCH + PTT group will receive the full 4 series of 8 Xiaflex injections with 1-3 days between each set of 2 injections and 6 weeks prior to the next series. Patients would then use the RestoreX traction device throughout the series to 3 months post-treatment. Those that were assigned the surgery + PTT treatment protocol would undergo surgery using either penile plication or incision and grafting, depending on the degree of curvature and erectile function. Traction using RestoreX will also be prescribed to these men 2-4 weeks post-operatively until 3 months post-treatment. Key clinical outcomes of both treatment protocols will be compared.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CCH+PTT | Active Comparator | Men will receive two injections of CCH administered 1-3 days apart, followed by manual modeling and PTT 30-60 min/day as outlined in our prior publication. Approximately 6 weeks later, the next round of injections will be performed until a maximum of 8 injections in total has been administered. PTT will be continued until the 3-month post-treatment visit. |
|
| Surgery+PTT | Active Comparator | Men will undergo either penile plication or I&G based on appropriate clinical criteria for either surgery. 2-4 weeks post-operatively (depending on tolerability), the patients will be asked to perform PTT 30-60 minutes daily until the 3-month post-treatment visit. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH) | Drug | Men in this cohort would receive the full series of 8 Xiaflex injections: 2 injections separated by 1-3 days, repeated 3 additional times with 6 week breaks between treatments. |
| Measure | Description | Time Frame |
|---|---|---|
| Overall satisfaction with treatment | Answer to SAPS question #1 (How satisfied are you with the effect of your treatment?) to determine overall satisfaction at all time points | 1 year |
| Subjective reporting of erectile dysfunction post treatment | Comparison of erectile dysfunction complication rates | 1 year |
| Subjective reporting of changes in penile sensation post treatment | Comparison of changes in penile sensation complication rates | 1 year |
| Subjective reporting of changes in penile length post treatment | Comparison of perceived changes in penile length complication rates | 1 year |
| International Index of Erectile Function, Erectile Function Domain (IIEF) Scores | Comparison of IIEF erectile function domain score (Q1-5, 15; min/max 1-30; higher is better) | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Peyronie's Disease Questionnaire (PDQ) Scores | Comparison of PDQ questionnaire scores; Subdomains - psychological and physical (Q1-6; min/max 0-24; lower is better), penile pain (Q7-9; min/max 0-30; lower is better), symptom bother (Q10-15; min/max 0-16; lower is better) | 1 year |
| International Index of Erectile Function (IIEF) Scores |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Male Fertility and Peyronie's Clinic | Orem | Utah | 84057 | United States |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Dec 11, 2020 | Jan 28, 2021 |
Not provided
Not provided
Not provided
Not provided
The curvature and length assessments will be performed without knowledge as to pre-treatment measurements.
|
| Penile Plication Surgery | Procedure | Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures <70 degrees; I&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&G) will ultimately be decided based on the primary investigator's clinical judgment. |
|
| Incision and Grafting (I&G) Surgery | Procedure | Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures <70 degrees; I&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&G) will ultimately be decided based on the primary investigator's clinical judgment. |
|
| RestoreX Penile Traction Device | Device | RestoreX is a Class I PTT device developed by PathRight Medical, is registered with the FDA, and has randomized controlled data demonstrating efficacy when used for the treatment of PD. |
|
Comparison of IIEF questionnaire scores-all domains except erectile function (which is a primary endpoint); subdomains: orgasmic function (Q9-10; min/max 0-10; higher is better), sexual desire (Q11-12; min/max 2-10; higher is better), intercourse satisfaction (Q6-8; min/max 0-15; higher is better), overall satisfaction (Q13-14; min/max 2-10; higher is better) |
| 1 year |
| Beck's Depression Inventory (BDI) Scores | Comparison of BDI questionnaire scores on depression. 21 items (min/max 0-63, lower is better) | 1 year |
| Penile Curvature | Comparison of changes in penile curvature | 1 year |
| Objective measurements of penile length post treatment (compared to pre-treatment) | Comparison of changes in penile length | 1 year |
| Interventions required | Comparison of subsequent interventions required - surgery or CCH injections | 1 year |
| Hospitalizations | Number of hospitalizations or ER visits resulting from treatment | 1 year |
| Non-standardized questionnaire | Comparison of non-standardized questionnaire responses | 1 year |
| Prot_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Dec 28, 2020 | Jan 28, 2021 | ICF_001.pdf |
| ID | Term |
|---|---|
| D010411 | Penile Induration |
| D000072836 | Surgical Wound |
| ID | Term |
|---|---|
| D010409 | Penile Diseases |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D014947 | Wounds and Injuries |
Not provided
Not provided
| ID | Term |
|---|---|
| D003012 | Microbial Collagenase |
| D014180 | Transplantation |
| D013514 | Surgical Procedures, Operative |
| ID | Term |
|---|---|
| D017364 | Collagenases |
| D008666 | Metalloendopeptidases |
| D010450 | Endopeptidases |
| D010447 | Peptide Hydrolases |
| D006867 | Hydrolases |
| D004798 | Enzymes |
| D045762 | Enzymes and Coenzymes |
| D045726 | Metalloproteases |
Not provided
Not provided